• About
  • Advertise
  • Careers
  • Contact
Sunday, July 20, 2025
  • Login
No Result
View All Result
NEWSLETTER
Reporters At Large
  • Home
  • News
    • World
    • For The Record
    • Metro
    • Opinion
    • Press Releases
  • Business
    • Auto Trend
  • Politics
  • Tourism
  • Lifestyle
    • People & Events
    • Health
  • RAL TV
    • Video
    • Video News
  • More
    • Advertisement
    • Privacy
    • Disclaimer
    • Contact Us
  • Home
  • News
    • World
    • For The Record
    • Metro
    • Opinion
    • Press Releases
  • Business
    • Auto Trend
  • Politics
  • Tourism
  • Lifestyle
    • People & Events
    • Health
  • RAL TV
    • Video
    • Video News
  • More
    • Advertisement
    • Privacy
    • Disclaimer
    • Contact Us
No Result
View All Result
Reporters At Large
No Result
View All Result
Home Featured

Oxford University COVID-19 Vaccine Trial Suspended After Participant Falls Ill

by ReportersAtLarge
September 9, 2020
in Featured
Reading Time: 4 mins read
0
Blood cancer patients are more likely to die from coronavirus than patients with other forms of the disease
Share on WhatsappShare on FacebookShare on TwitterShare on Linkedin

Final clinical trials for a coronavirus vaccine, developed by AstraZeneca and Oxford University, have been put on hold after a participant had a suspected adverse reaction in the UK.

AstraZeneca described it as a “routine” pause in the case of “an unexplained illness”.

The outcome of vaccine trials is being closely watched around the world.

The AstraZeneca-Oxford University vaccine is seen as a strong contender among dozens being developed globally.

Hopes have been high that the vaccine might be one of the first to come on the market, following successful phase 1 and 2 testing.

RelatedPosts

Bangladesh President Dissolves Parliament, Prepares For Interim Government

Tim Walz: Who Is Kamala Harris’ VP Running Mate?

US Elections: Kamala Harris Picks Tim Walz As Running Mate

Its move to Phase 3 testing in recent weeks has involved some 30,000 participants in the US as well as in the UK, Brazil and South Africa. Phase 3 trials in vaccines often involve thousands of participants and can last several years.

Stat News, the health website which first broke the story, said details of the UK participant’s adverse reaction were not immediately known, but quoted a source as saying they were expected to recover.

Decision on restarting trial could be days away

At first glance this may seem alarming. A vaccine trial – and not just any vaccine, but one receiving massive global attention – is put on hold due to a suspected serious adverse reaction. But such events are not unheard of. Indeed the Oxford team describe it as “routine”. Any time a volunteer is admitted to hospital and the cause of their illness is not immediately apparent it triggers a study to be put on hold.

This is actually the second time it has happened with the Oxford University/AstraZeneca coronavirus vaccine trial since the first volunteers were immunised in April. An Oxford University spokesperson said: “In large trials, illnesses will happen by chance but must be independently reviewed to check this carefully.”

A final decision on restarting the trial will be taken by the medical regulator the MHRA, which could take only days. But until then all international vaccination sites, in the UK, Brazil, South Africa and the USA are on hold.

The Oxford University team believe this process illustrates that they are committed to the safety of their volunteers and the highest standards of conduct in their studies.

Where are we in the search for a vaccine?

US President Donald Trump has said he wants a vaccine available in the US before 3 November’s election, but his comments have raised fears that politics may be prioritised over safety in the rush for a vaccine.

On Tuesday, a group of nine Covid-19 vaccine developers sought to reassure the public by announcing a “historic pledge” to uphold scientific and ethical standards in the search for a vaccine.

AstraZeneca is among the nine firms who signed up to the pledge to only apply for regulatory approval after vaccines have gone through three phases of clinical study.

Industry giants Johnson & Johnson, BioNTech, GlaxoSmithKline, Pfizer, Merk, Moderna, Sanofi and Novavax are the other signatories.

They pledged to “always make the safety and well-being of vaccinated individuals our top priority”.

The World Health Organization (WHO) says nearly 180 vaccine candidates are being tested around the world but none has yet completed clinical trials.

The organisation has said it does not expect a vaccine to meet its efficacy and safety guidelines in order to be approved this year because of the time it takes to test them safely.

Similar sentiments have been shared by Thomas Cueni, director-general of the International Federation of Pharmaceutical Manufacturers. The industry body represents the companies that signed the pledge.

Despite this, China and Russia have begun inoculating some key workers with domestically developed vaccines. All of them are still listed by the WHO as being in clinical trials.

Meanwhile, the US national regulator, the Food and Drug Administration (FDA), has suggested that coronavirus vaccines may be approved before completing a third phase of clinical trials.

Last week it also emerged that the US Centers for Disease Control and Prevention had urged states to consider waiving certain requirements in order to be ready to distribute a potential vaccine by 1 November – two days before the 3 November presidential election.

Although President Trump has hinted that a vaccine might be available before the election, his Democratic rival Joe Biden has expressed scepticism that Mr Trump will listen to scientists and implement a transparent process.

Tags: AstraZenecaCoronavirus TestingMers VirusOxford UniversityVaccination
SendShare20TweetShare
ReportersAtLarge

ReportersAtLarge

Reporters At Large is the world’s fastest-growing online news platform and public service broadcaster. We’re impartial and independent, and every day we create distinctive, world-class programmes and content which inform, educate and entertain millions of people in Nigeria and around the world.

More

Bangladesh Parliament Building
Featured

Bangladesh President Dissolves Parliament, Prepares For Interim Government

by ReportersAtLarge
August 6, 2024
0

Bangladesh's president dissolved parliament on Tuesday, clearing the way for an interim government and new elections a day after Prime...

Read moreDetails
Tim Walz
Featured

Tim Walz: Who Is Kamala Harris’ VP Running Mate?

by ReportersAtLarge
August 6, 2024
0

Minnesota Governor Tim Walz has been selected as the running mate for Democratic nominee Vice President Kamala Harris. Harris announced...

Read moreDetails
US Elections - Kamala Harris picks Tim Walz as Running Mate
Featured

US Elections: Kamala Harris Picks Tim Walz As Running Mate

by ReportersAtLarge
August 6, 2024
0

U.S. Vice President Kamala Harris has chosen Minnesota Gov. Tim Walz as her running mate, looking to strengthen the Democratic...

Read moreDetails
Load More

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Senator Godswill Akpabio in Cross River State

Cross River ‘ll Take Its Rightful Place Under My Presidency – Akpabio

3 years ago
Senator Iyiola Omisore

NISafetyE 2021: Omisore To Deliver Keynote Address

4 years ago

Popular News

  • Governor Biodun Oyebanji of Ekiti State

    Why The Symphony Of Endorsements For Governor Oyebanji?

    0 shares
    Share 0 Tweet 0
  • Man Sentenced To 400-Year Imprisonment Found Innocent After 34 Years In Prison, Awarded $1.7m

    0 shares
    Share 0 Tweet 0
  • Makinde, wife installed as Aare Omoluabi, Yeye Aare Omoluabi Of Akure Kingdom

    0 shares
    Share 0 Tweet 0
  • Toyin Kolade: Four Wasteful Years As Iyalaje Oodua?

    0 shares
    Share 0 Tweet 0
  • Kano University Tops The List As JAMB Uncovers Over 9,000 Illegal Admissions In Nigerian Tertiary Institutions

    0 shares
    Share 0 Tweet 0

Connect with us

ADVERTISEMENT

About Us

Reporters At Large is the world’s fastest-growing online news platform and public service broadcaster. We’re impartial and independent, and every day we create distinctive, world-class programmes and content which inform, educate and entertain millions of people in Nigeria and around the world.

With a high level of professionalism, fairness, objectivity, accuracy and speed, we publish Breaking News Nigeria Today Headlines and International news on Politics, Tourism and Travel, Entertainment, Sports, Business Lifestyle and Sports.

Category

  • Auto Trend
  • Breaking Bones
  • Business
  • Columns
  • Entertainment
  • Featured
  • For The Record
  • Health
  • Innovation
  • Lifestyle
  • Metro
  • News
  • Opinion
  • People & Events
  • Politics
  • Press Releases
  • Science & Technology
  • Sponsored
  • Sport
  • Tourism & Culture
  • Video
  • Video News
  • WorldNews

Recent Posts

  • Why The Symphony Of Endorsements For Governor Oyebanji? July 19, 2025
  • Man Sentenced To 400-Year Imprisonment Found Innocent After 34 Years In Prison, Awarded $1.7m July 19, 2025
  • Makinde, wife installed as Aare Omoluabi, Yeye Aare Omoluabi Of Akure Kingdom July 18, 2025
  • WAFCON: Super Falcons crush Zambia 5-0 July 18, 2025
  • Toyin Kolade: Four Wasteful Years As Iyalaje Oodua? July 18, 2025
September 2020
SMTWTFS
 12345
6789101112
13141516171819
20212223242526
27282930 
« Aug   Oct »
  • Home
  • News
  • Business
  • Politics
  • Tourism
  • Lifestyle
  • RAL TV
  • More

© 2016-2024 RAL - Guided by professionalism

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • World
    • For The Record
    • Metro
    • Opinion
    • Press Releases
  • Business
    • Auto Trend
  • Politics
  • Tourism
  • Lifestyle
    • People & Events
    • Health
  • RAL TV
    • Video
    • Video News
  • More
    • Advertisement
    • Privacy
    • Disclaimer
    • Contact Us

© 2016-2024 RAL - Guided by professionalism

Verified by MonsterInsights